3B BlackBio says flu spike added ₹5.5 crore to Q2 sales

3B BlackBio reported standalone sales of ₹33.25 crore in Q2 2026-27, up 36.1% from ₹24.44 crore a year earlier, but management said a seasonal flu spike in India contributed about ₹5.5 crore and has now subsided. 3B plans to pursue exports, new products and contractual business to reduce exposure to such demand swings.

How much of 3B's Q2 sales increase came from flu?

The seasonal flu spike added about ₹5.5 crore to 3B’s standalone sales in Q2 2026-27, according to management, and was not present in Q2 2025-26. Standalone sales increased by ₹8.81 crore, from ₹24.44 crore in Q2 2025-26 to ₹33.25 crore in Q2 2026-27, producing the reported 36.1% year-on-year growth.

On a calculation using management’s approximate flu-sales figure, the spike accounted for about 62% of the ₹8.81 crore year-on-year increase. Subtracting ₹5.5 crore from Q2 2026-27 standalone sales leaves about ₹27.75 crore, above the ₹24.44 crore reported in Q2 2025-26. This is an analytical comparison, not management guidance on recurring sales.

Management said the flu event occurred in India and has subsided, so the reported 36.1% increase combines ordinary sales activity with temporary seasonal demand. Its response for FY 2026-27 includes export marketing, distributor additions, product development and contracts under which laboratories and hospitals use 3B assays.

What did 3B report for Q2 sales and exports?

3B reported revenue from operations of ₹45.02 crore in Q2 2026-27, compared with ₹30.43 crore in Q2 2025-26. The Q2 2026-27 total included ₹6.83 crore of sales from TRUPCR Europe Limited, Manchester, and ₹9.17 crore from Coris BioConcept SRL, Belgium, alongside 3B’s ₹33.25 crore standalone sales.

Exports rose by ₹1.60 crore to ₹6.57 crore in Q2 2026-27 from ₹4.98 crore a year earlier. The presentation does not break those exports down by country, product or legal entity, but it says 3B operates in more than 70 countries and is expanding in Africa through channel-partner relationships.

The company’s H1 2026-27 revenue from operations was ₹77.08 crore, including ₹17.80 crore of Coris sales, compared with ₹50.39 crore in H1 2025-26. Excluding Coris, revenue from operations rose 27.1% to ₹59.45 crore from ₹46.76 crore, providing a separate half-year comparison alongside the flu-affected Q2 standalone result.

How does 3B plan to replace seasonal demand?

3B plans to use international marketing, distributor expansion, regulatory work and new product categories to help offset future seasonal spikes. Management said it would participate in Medica in Dusseldorf from 16 to 19 November 2026 and WHX Labs in Dubai from 25 to 28 January 2027 while exploring other international events.

The company said it is strengthening its marketing team and expanding its distributor network into new markets. It also said it had passed an In Vitro Diagnostic Regulation quality management system audit and was complying with provisions needed to obtain certification in due course, without providing a certification date.

3B is developing an original equipment manufacturer Sample to Answer system to enter another market segment. It has also developed lyophilised products that are in final validation; management said that revenue from this range may not be large as a percentage of sales but could help it maintain projected growth.

For FY 2026-27, management said it hopes to grow combined domestic and export sales by 15% to 20%, while noting that geopolitical tensions are affecting sales currently. It estimates India’s molecular diagnostics market at about ₹500 crore to ₹600 crore, puts its own market share at about 15%, and cites expected industry growth of 8% to 10% over the next few years.

What are 3B's sales models in India?

3B says other supplies to hospitals and laboratories represent 65% to 70% of India sales, while contractual or reagent-rental business is projected to contribute 20% to 25% in the current financial year and coming years. Tender sales account for about 5% to 7%, depending on the tender type.

Under the contractual model, 3B provides molecular diagnostic equipment, including real-time polymerase chain reaction systems and automated or manual extraction systems, to laboratories and hospitals. Customers must use 3B assays, and management describes these as long-term contracts, making the projected 20% to 25% contribution a mechanism separate from a one-quarter flu spike.

Other supplies remain the largest disclosed channel at 65% to 70% of India sales. Tender sales are the smallest at 5% to 7%, while the contractual share is projected rather than reported as an achieved result for FY 2026-27.

How is 3B handling customer credit terms?

3B says it follows a liberal credit policy to increase sales and avoid losing customers to competitors offering less rigid payment terms. Management said this approach has resulted in higher debtor levels currently and that it intends to reduce them gradually over coming years.

The presentation does not disclose the debtor balance, collection period or a timetable for reducing debtors. That leaves the future effect of the policy unresolved as 3B seeks 15% to 20% overall FY 2026-27 growth and expands sales through the 65% to 70% other-supplies channel and longer-term contractual arrangements.

Conclusion

3B’s Q2 2026-27 standalone growth included an approximately ₹5.5 crore domestic flu-led sales event that management says has ended. Reported revenue also reflected higher exports, at ₹6.57 crore versus ₹4.98 crore a year earlier, while the company’s H1 revenue excluding Coris rose 27.1% to ₹59.45 crore.

The next developments to watch are 3B’s participation at Medica in November 2026 and WHX Labs in January 2027, final validation of lyophilised products and the timing of In Vitro Diagnostic Regulation certification. Management’s 15% to 20% FY 2026-27 growth hope, projected 20% to 25% contractual-sales contribution and planned reduction in debtors remain the stated measures of progress after the flu spike.